Phaseline

Targets › APELIN

APELIN: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Cardiovascular; next expected readout Dec 2026.

Open in Phaseline: the race on APELIN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Cambridge University Hospitals NHS Foundation TrustApelin
Apelin receptor agonist; activates G protein-coupled receptor to inhibit insulin secretion
APELINPhase 2Cardiovascular DiseasesDec 2026

Conditions

Cardiovascular Diseases (1)

Modalities

small molecule (1)

Companies

Cambridge University Hospitals NHS Foundation Trust (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.